VX18-147-001
36 evidence topics · 1 source
Objective
Aims of the two phase 1 studies
“We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Herein we report the safety, tolerability, and pharmacokinetics of inaxaplin from two phase 1 single-ascending dose (SAD)/multiple-ascending dose (MAD) studies in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-in-human study VX18-147-001
“The first-in-human study of inaxaplin (Study VX18-147-001 or Study 1) evaluated single ascending doses of 7.5 mg up to 50 mg and multiple ascending doses of 15 mg once daily, 15 mg twice daily, or 45 mg once daily in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary objective: safety and tolerability
“The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CYP3A4 interaction objective in Study 1
“We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study design
Randomized, double-blind, placebo-controlled SAD/MAD design
Part A single ascending doses and Part B multiple ascending doses
“Part A of both phase 1 studies was designed to evaluate the safety and tolerability of single oral ascending doses of inaxaplin administered to healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Part B of both phase 1 studies was designed to evaluate the safety and tolerability of multiple oral ascending doses of inaxaplin administered to healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unique participants per cohort and safety follow-up
“All SAD and MAD cohorts included unique participants. There was no cross-over of participants within or across study cohorts. All participants had a Safety Follow-up Visit 7–10 days after the last dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Healthy adults of non-childbearing potential
“In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“was defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, standard 12-lead electrocardiogram (ECG), and clinical laboratory tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single doses of 7.5 to 50 mg or placebo in Part A of Study 1
Multiple doses for 14 days or placebo in Part B of Study 1
Study outcomes
Rationale for using safety and tolerability assessments as the primary endpoints
Primary safety and tolerability endpoints
“The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic assessments
“In both studies, we assessed plasma pharmacokinetic (PK) parameter estimates of inaxaplin (i.e., time of maximum concentration [tmax], maximum observed concentration [Cmax], area under the concentration vs. time curve from the time of dosing to 24 h [AUC0–24h], terminal phase half-life [t½], apparent volume of distribution [V/F], and apparent clearance at steady-state [CLss/F]) after multiple oral ascending doses of inaxaplin derived from plasma concentration-time data. We also assessed urine PK parameter estimates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Midazolam as a sensitive CYP3A4 substrate
“We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized and dosed across both studies
“One hundred and seventy eight participants were randomized and received at least one dose of study drug in the SAD and MAD cohorts of the two phase 1 studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 21 participants who received placebo in the SAD cohort and 23 participants who received placebo in the MAD cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 63 participants who received inaxaplin in the SAD cohort and 71 participants who received inaxaplin in the MAD cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants per group in the MAD cohorts of Study 1
“Inaxaplin 15 mg once daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin 15 mg twice daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin 45 mg once daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Placebo is pooled from all MAD cohorts in Study 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety set and descriptive analyses
“N, Safety Set sample size” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This table includes all participants in the MAD cohorts of Study 1 who received at least one dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both phase 1 studies, we used descriptive analyses on safety data including AEs, clinical laboratory assessments, vital signs, and ECGs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Triplicate ECGs and pooled analysis across cohorts
“Since ECGs were performed in triplicate, the mean of each individual ECG parameter measurement (i.e., PR, RR, QRS, QT, QTcF, heart rate) at each specific visit and time point was used as the ECG for that specific visit and time point for summary purposes. In addition to analyses performed in the SAD and MAD cohorts separately for the two studies, we conducted a pooled analysis across cohorts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Discontinuation for papular rash in the 45 mg once daily group of Study 1
Disposition pooled across Study 1 and Study 2
| Disposition | Placebo | Inaxaplin total |
|---|---|---|
| Completed study drug (SAD only), n/N (%) | “21/21 (100.0)”View highlighted excerpt for this quote | “63/63 (100.0)”View highlighted excerpt for this quote |
| Completed study drug (MAD only), n/N (%) | “18/23 (78.3)”View highlighted excerpt for this quote | “50/71 (70.4)”View highlighted excerpt for this quote |
| Discontinued study drug (MAD only), n/N (%) | “5/23 (21.7)”View highlighted excerpt for this quote | “21/71 (29.6)”View highlighted excerpt for this quote |
| Discontinued for adverse event | “0”View highlighted excerpt for this quote | “3/71 (4.2)”View highlighted excerpt for this quote |
| Participant refused further dosing (not due to AE) | “0”View highlighted excerpt for this quote | “1/71 (1.4)”View highlighted excerpt for this quote |
| Other non-adherence | “0”View highlighted excerpt for this quote | “1/71 (1.4)”View highlighted excerpt for this quote |
| Sponsor decision | “5/23 (21.7)”View highlighted excerpt for this quote | “16/71 (22.5)”View highlighted excerpt for this quote |
Baseline characteristics
Demographics pooled across Study 1 and Study 2
Age and comparability of groups
Efficacy results
Dose proportionality and half-life across both studies
“The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1). Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal clearance as a minor excretion pathway
“Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No clinically significant interaction with midazolam
“There were no clinically significant PK drug-drug interactions between inaxaplin and midazolam (online Table S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin is not a clinically significant inhibitor or inducer of CYP3A4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Adverse events in the MAD cohorts of Study 1
Papular rash leading to discontinuation in Study 1
“One participant in the inaxaplin 45 mg once daily MAD group in Study 1 discontinued treatment due to an AE of papular rash, which was mild in severity, resolved without treatment, and was considered unlikely related to the study drug by the investigator (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events pooled across Study 1 and Study 2
Severity, relatedness, and headache across both studies
“All AEs were mild or moderate in severity. None of the AEs were considered by the investigator as related to inaxaplin. There were no serious adverse events (SAEs) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most of these AEs had similar or lower incidences in the inaxaplin group compared to placebo, except for headache (10.4% in the inaxaplin group compared to 2.3% in the placebo group) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of headache was lower in participants treated with doses of inaxaplin ≤45 mg once daily (11.1%) than in those treated with doses of inaxaplin ≥60 mg once daily (18.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory values, vital signs, and ECG parameters
“During the course of the SAD and MAD cohorts of both phase 1 studies, no clinically relevant trends were noted in any of the clinical laboratory results. Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no evidence of effects of inaxaplin on ECG parameters. There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec. No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: study limitations
VX18-147-001 enrolled healthy adults, so its safety findings do not describe people with APOL1-mediated kidney disease. Multiple dosing lasted 14 days, and each MAD group of Study 1 had 9 participants receiving inaxaplin (15 mg once daily, 15 mg twice daily, or 45 mg once daily) and 9 receiving pooled placebo. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. The publication reports demographics, disposition, and the overall adverse event table pooled across Study 1 and Study 2, and gives the pharmacokinetic parameter estimates, including the midazolam interaction results, only in online supplementary tables. The trials were designed and funded by Vertex Pharmaceuticals, and four of the authors are Vertex employees who own stock or stock options in the company.
Sponsor funding and employment
“These studies were supported by Vertex Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drs. Ogo Egbuna, George Manos, Simon Tian, and Fanuel Hagos are employees of Vertex Pharmaceuticals and own stock or stock options in the company.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote